Feast or famine in multiple sclerosis therapeutics

Over the past 30 years, the number of drugs approved for multiple sclerosis has gone from zero to more than 15, with several dosing variations and generic versions. Despite this great progress, current multiple sclerosis treatments seem to predominantly benefit the inflammatory lesion activity that underlies relapsing multiple sclerosis, leaving the progressive aspects (ie, gradual disability worsening without clinical relapses) mostly unabated....